values for levofloxacin Search Results


values for levofloxacin  (ATCC)
95
ATCC values for levofloxacin
Values For Levofloxacin, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/values+for+levofloxacin/Streptococcus+pneumoniae/pm22210757-56-67-84
Average 95 stars, based on 1 article reviews
values for levofloxacin - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
levofloxacin m.i.c.evaluator strips (m.i.c.e. )  (Thermo Fisher)
N/A
Effortlessly establish accurate Minimum Inhibitory Concentration (MIC) values manually using Thermo Scientific™ Oxoid™ Levofloxacin M.I.C.Evaluator Strips (M.I.C.E.™).
   Buy from Supplier
mic values against levofloxacin  (ATCC)
99
ATCC mic values against levofloxacin
In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
Mic Values Against Levofloxacin, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/values+for+levofloxacin/MIC/pmc08343939-139-22-55
Average 99 stars, based on 1 article reviews
mic values against levofloxacin - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
results ampicillin piperacillin teicoplanin ciprofloxacin levofloxacin meropenem erythromycin e coli  (ATCC)
99
ATCC results ampicillin piperacillin teicoplanin ciprofloxacin levofloxacin meropenem erythromycin e coli
In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of <t>MIC</t> values against <t>levofloxacin</t> of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control
Results Ampicillin Piperacillin Teicoplanin Ciprofloxacin Levofloxacin Meropenem Erythromycin E Coli, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/values+for+levofloxacin/Escherichia+coli+(Migula)+Castellani+and+Chalmers/10__1046_slash_j__1469___0691__9__s1__83__x-19785-20-30
Average 99 stars, based on 1 article reviews
results ampicillin piperacillin teicoplanin ciprofloxacin levofloxacin meropenem erythromycin e coli - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

Image Search Results


In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control

Journal: Chinese Medicine

Article Title: Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa

doi: 10.1186/s13020-021-00481-8

Figure Lengend Snippet: In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC. *P < 0.05, compared with corresponding control

Article Snippet: Fig. 1 In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC.

Techniques: In Vitro, Control

Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control

Journal: Chinese Medicine

Article Title: Quinic acid: a potential antibiofilm agent against clinical resistant Pseudomonas aeruginosa

doi: 10.1186/s13020-021-00481-8

Figure Lengend Snippet: Active antibiofilm compounds from metabolites of CA in LJF. a Antibiofilm activity of LJF and CA. b Growth curves of bacterial growth at different sub-MICs of CA. c GC–MS analysis of CA at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of CA. d Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of CA. e Metabolic pathways of CA in intestine (left) and liver (right). f In vitro antibiofilm effects of CA and its intestinal metabolites. g In vitro antibiofilm effects of CA and its liver metabolites. h GC–MS analysis of quinic acid at 0.5, 1, 2, 4, 6, 24 h. The red arrow indicates the location of the peak of quinic acid. i Measured ion spectrum (upper) and matched ion spectrum in NIST17 database (lower) of quinic acid. j The antibacterial activity ratio of caffeic acid and quinic acid to CA. k The antibacterial activity ratio of caffeic acid and its main metabolites to CA. l , m The antibacterial activity ratio of quinic acid and its major metabolites to CA. n – o Effects of dihydrocaffeic acid and gallic acid on the integrity (n) and the permeability (o) of bacteria membrane against MRSA. p - q Effects of dihydrocaffeic acid on the integrity ( p ) and the permeability ( q ) of bacteria membrane against MSSA. r Effects of quinic acid on EPS secretion in biofilm formation (upper) and in mature biofilm (lower). s – u The synergistic antibiofilm effects of sub-MIC quinic acid with levofloxacin ( s ), clarithromycin ( t ) and azithromycin ( v ). QA: quinic acid. *P < 0.05, **P < 0.01, compared with corresponding control

Article Snippet: Fig. 1 In vitro screening of 13 plant extracts with antibiofilm activities against clinical resistant isolates of PA. a The distribution of MIC values against levofloxacin of 96 clinical isolates of PA. b The level of biofilm formation in 12 resistant strains of PA. c The MIC values of 13 plant extracts against PA1803 and ATCC 27853. d The antibiofilm activities of 13 plant extracts against PA1803 at MIC and 1/2MIC.

Techniques: Activity Assay, Gas Chromatography-Mass Spectrometry, In Vitro, Permeability, Bacteria, Membrane, Control